[go: up one dir, main page]

PA8606901A1 - Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 - Google Patents

Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3

Info

Publication number
PA8606901A1
PA8606901A1 PA20048606901A PA8606901A PA8606901A1 PA 8606901 A1 PA8606901 A1 PA 8606901A1 PA 20048606901 A PA20048606901 A PA 20048606901A PA 8606901 A PA8606901 A PA 8606901A PA 8606901 A1 PA8606901 A1 PA 8606901A1
Authority
PA
Panama
Prior art keywords
optionally replaced
replaced
alquiloc1
nr9r10
members
Prior art date
Application number
PA20048606901A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Marc Willems
Christopher John Love
Ludwig Paul Cooymans
Nele Vandermaesen
Peter Jaobus Johannes Antonius Buijnsters
Werner Constant Johan Embrechts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PA8606901A1 publication Critical patent/PA8606901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPUESTOS DE FORMULA UN N-OXIDO, UNA SAL DE ADICION FARMACEUTICAMENTE ACEPTABLE, UNA AMINA CUATERNARIA Y UNA FORMA ESTEREOQUIMICAMENTE ISOMERICA DE LOS MISMOS, DONDE EL ANILLO A REPRESENTA FENILO, PIRIDILO, PIRIMIDINILO, PIRIDAZINILO O PIRAZINILO; R1 REPRESENTA HIDROGENO; ARILO; FORMILO; ALQUILCARBONILOC1-6; ALQUILOC1-6; ALQUILOXICARBONILOC1-6; ALQUILOC1-6 SUSTITUIDO CON FORMILO, ALQUILCARBONILOC1-6, ALQUILOCICARBONILOC1-6, ALQUILCARBONILOXIC1-6; O ALQUILOXIC1-6ALQUILCARBONILOC1-6 OPCIONALMENE SISTITUIDO; X1 REPRESENTA UN ENLACE DIRECTO; -(CH2)N3- O -(CH2)N4-X1A-X1B-; R2 REPRESENTA CICLOALQUILOC3-7 OPCIONALMENTE SUSTITUIDO; FENILO; UN HETEROCICLO MONOCICLICO DE 4,5,6 O 7 MIEMBROS QUE CONTIENEN AL MENOS UN HETEROATOMO SELECCIONADO ENTRE O,S o N; BENZOXAZOLILO O UNRADICAL DE FORMULA X2 REPRESENTA UN ENLACE DIRECTO; -NR1-; -NR1-(CH2)N3-; -O-; -O-(CH2)N3-; -C(=O)-; -C(=O)- (CH2)N3-; -C(=O)-NR5-(CH2)N3; -C(=S)-; -S-; -S)=0)N1-; -(CH2)N3-; -(CH2)N4-X1A-1B-; -X1A-X1B-(CH2)N4-; -S(=O)N1-NR5-(CH2)N3-NR5-O-S(=O)N1-NR5-(CH2)N3-; R3 REPRESENTA UN HERETOCICLO MONOCICLICO DE 5 O 6 MIEMBROS OPCIONALMENTE SISTITUIDO QUE CONTIENE POR LO MENOS UN HETEROATOMO SELECCIONADO ENTRE O, S O N, O UN HETEROCICLO BICICLICO DE 9 O 10 MIEMBROS QUE CONTIENE POR LO MENOS UN HETEROATOMO SELECCIONADO ENTRE O, S O N; R4 REPRESENTA HIDROGENO; HALO; HIDROXI; ALQUILOC1-4 OPCIONALMENTE SUSTITUIDO; ALQUENILOC2-4 OPCIONALMENTE SUSTITUIDO; O ALQUINILO C2-4; POLIHALOALQUILOC1-3; ALQUILOXIC1-4 OPCIONALMENTE SUSTITUIDO; POLIHALOALQUILOXIC1-3; ALQUILTIOC1-4; POLIHALOALQUILTIOC1-3; ALQUILOXICARBONILOC1-4; ALQUILCARBONILOXIC1-4; ALQUILCARBONILOC1-4; POLIHALOALQUILCARBONILOC1-4; NITRO; CIANO; CARBOXILO; NR9R10; C(=O)NR9R10;-NR5-C(=O)-NR9R10; -NR5-C(=O)-R5; -S(=O)N1-R11; -NR5-S(=O)N1-R11; -S-CN; -NR5-CN; SU USO, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y PROCESOS PARA SU PREPARACION.
PA20048606901A 2003-07-16 2004-07-15 Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 PA8606901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP0350314 2003-07-16

Publications (1)

Publication Number Publication Date
PA8606901A1 true PA8606901A1 (es) 2005-05-24

Family

ID=34112426

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048606901A PA8606901A1 (es) 2003-07-16 2004-07-15 Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3

Country Status (13)

Country Link
US (1) US7449465B2 (es)
EP (1) EP1781659B1 (es)
JP (1) JP2007526894A (es)
CN (1) CN100549014C (es)
AR (1) AR045699A1 (es)
AT (1) ATE413404T1 (es)
CA (1) CA2531232A1 (es)
DE (1) DE602004017654D1 (es)
EA (1) EA011300B1 (es)
ES (1) ES2317031T3 (es)
PA (1) PA8606901A1 (es)
TW (1) TW200519115A (es)
WO (1) WO2005012304A2 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003265336B8 (en) 2002-07-29 2009-04-23 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
KR101201603B1 (ko) 2003-07-30 2012-11-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물
EP1660458B1 (en) * 2003-08-15 2012-01-25 Novartis AG 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
US7138401B2 (en) * 2003-09-18 2006-11-21 Conforma Therapeutics Corporation 2-aminopurine analogs having HSP90-inhibiting activity
TW200626139A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
CN101083982A (zh) 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
ES2508766T3 (es) 2004-10-29 2014-10-16 Janssen R&D Ireland Derivados de pirimidina bicíclicos que inhiben el VIH
US7563781B2 (en) 2005-01-14 2009-07-21 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1904457B1 (en) 2005-06-08 2017-09-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100048660A1 (en) * 2006-02-10 2010-02-25 Graham Michael Wynne Treatment of duchenne muscular dystrophy
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
US7968536B2 (en) * 2007-06-29 2011-06-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as RAF kinase inhibitors
TWI444379B (zh) 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Ｒａｆ激酶抑制劑之化合物
GB0715087D0 (en) * 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2009145814A2 (en) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
EP2367826A4 (en) 2008-11-06 2012-07-04 Astrazeneca Ab MODULATORS OF THE PROTEIN -AMYLOID
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
UY32622A (es) * 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
PT2442809T (pt) 2009-06-17 2016-12-06 Vertex Pharma Inibidores da replicação de vírus da gripe
RU2528386C2 (ru) 2010-05-21 2014-09-20 Кемилиа Аб Новые производные пиримидина
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ 新規のピリミジン誘導体
ES2741444T3 (es) 2013-11-13 2020-02-11 Vertex Pharma Inhibidores de la replicación de virus de la gripe
RS57541B1 (sr) 2013-11-13 2018-10-31 Vertex Pharma Postupci za pripremu inhibitora replikacije virusa gripa
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2017076900A1 (en) 2015-11-02 2017-05-11 Janssen Pharmaceutica Nv [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7-YL COMPOUND
JP7018944B2 (ja) 2016-11-02 2022-02-14 ヤンセン ファーマシューティカ エヌ．ベー． ＰＤＥ２阻害剤としての［１，２，４］トリアゾロ［１，５－ａ］ピリミジン化合物
EA039788B1 (ru) * 2016-11-02 2022-03-14 Янссен Фармацевтика Нв Производные [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2
CN109937202B (zh) 2016-11-02 2022-12-30 詹森药业有限公司 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物
RU2663913C1 (ru) * 2016-11-17 2018-08-13 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Твердая лекарственная форма антидиабетического препарата на основе N-замещенного производного амринона - ингибитора киназы гликогенсинтазы
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
MX2021013662A (es) 2019-05-10 2022-03-11 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
KR20220008873A (ko) 2019-05-10 2022-01-21 데시페라 파마슈티칼스, 엘엘씨. 페닐아미노피리미딘 아미드 자가포식 억제제 및 이의 사용 방법
CN112079836B (zh) * 2019-06-13 2022-12-13 中国科学院上海药物研究所 三唑并嘧啶类化合物及其盐、组合物和应用
MX2021015628A (es) 2019-06-17 2022-04-18 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5962594A (ja) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５―ジ置換―トリアゾロピリミジン誘導体
US6489344B1 (en) 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
TR200102969T2 (tr) 1999-04-15 2002-08-21 Bristol-Myers Squibb Company Siklik protein tirozin kinaz önleyicileri.
WO2001044246A1 (en) 1999-12-17 2001-06-21 Chiron Corporation Bicyclic inhibitors of glycogen synthase kinase 3
US20020040031A1 (en) * 2000-07-07 2002-04-04 Glasky Michelle S. Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
US6737085B2 (en) * 2000-11-01 2004-05-18 Tokiwa Phytochemical Co., Ltd. Apocynum venetum extract for use as antidepressant
AU2002222293A1 (en) * 2000-12-19 2002-07-01 Smithkline Beecham P.L.C. Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors
GB0100621D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives

Also Published As

Publication number Publication date
CA2531232A1 (en) 2005-02-10
AR045699A1 (es) 2005-11-09
ATE413404T1 (de) 2008-11-15
EP1781659A2 (en) 2007-05-09
EP1781659B1 (en) 2008-11-05
TW200519115A (en) 2005-06-16
DE602004017654D1 (de) 2008-12-18
US7449465B2 (en) 2008-11-11
EA011300B1 (ru) 2009-02-27
US20060183747A1 (en) 2006-08-17
ES2317031T3 (es) 2009-04-16
JP2007526894A (ja) 2007-09-20
WO2005012304A3 (en) 2007-04-26
CN1938308A (zh) 2007-03-28
CN100549014C (zh) 2009-10-14
AU2004260739A1 (en) 2005-02-10
EA200600257A1 (ru) 2006-06-30
WO2005012304A2 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
PA8606901A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
PA8607001A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
NO20071476L (no) Antidiuretiske midler.
GT200700036A (es) Compuestos fenil amido heterociclicos condensados
GT200300240A (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidinona sustituida por amino, fabricacion y uso de los mismos comoagentes farmaceuticos
AR057981A1 (es) Compuesto de pirroloquinolin -4- ona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios pra su preparacion
CR9772A (es) Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos
PA8796201A1 (es) Agentes anti-infecciosos y su uso
DOP2010000046A (es) Compuestos de biciclolactama sustituida
PE20050130A1 (es) Compuestos organicos
CO6280399A2 (es) Peptidil nitrilos y uso de los mismos como inhibidores de peptidil peptidasa i
GT200300226A (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos
AR048039A1 (es) Profarmacos de piperazina y agentes antivirales de piperidina sustituidos
GT200600341A (es) Inhibidores macrociclicos del virus de la hepatitis c
AR032165A1 (es) Carboxamidas heterociclicas, composiciones farmaceuticas, uso de dichas carboxamidas para preparar un medicamento como agentes antivirales y el uso in vitro para inhibir una dna polimerasa viral
GT200400133AA (es) Derivados de pirrolo[3,4-c] pirazol, activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. (solicitud fraccionaria no. 1, derivada de la patente no. pi-2004-0133).
CR9786A (es) Compuestos de bencimidazol-tiofeno
PA8576001A1 (es) "difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion , medicamentos que comprenden estos compuestos y su uso".
GT200300187A (es) Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas
PA8573501A1 (es) Derivados de benzoxazina y su empleo
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
PA8589801A1 (es) Aminoalcoxiindoles
PA8582201A1 (es) Indoles 2,7-sustituidos
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
PA8587501A1 (es) Benzoxazinonas sustituidas y usos de las mismas